The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
Eric Pujade-Lauraine
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Felix Hilpert
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
BĂ©atrice Weber
No relevant relationships to disclose
Alexander Reuss
No relevant relationships to disclose
Andres Poveda
Consultant or Advisory Role - Roche
Gunnar Kristensen
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
Roberto Sorio
No relevant relationships to disclose
Ignace B. Vergote
Consultant or Advisory Role - Roche
Petronella Witteveen
No relevant relationships to disclose
Aristotelis Bamias
Consultant or Advisory Role - Roche
Research Funding - Roche
Deolinda Pereira
Honoraria - Janssen-Cilag; Roche
Pauline Wimberger
Honoraria - Roche
Ana Oaknin
No relevant relationships to disclose
Mansoor Raza Mirza
Consultant or Advisory Role - Roche
Honoraria - Roche
Philippe Follana
No relevant relationships to disclose
David T. Bollag
Employment or Leadership Position - Roche
Stock Ownership - Roche
Isabelle Ray-Coquard
Honoraria - Amgen; Merck; Novartis; PharmaMar; Roche; Sanofi
Research Funding - Merck; Novartis; Roche